Puriblood Medical Co., Ltd.

Taipei Exchange 6847.TWO

Puriblood Medical Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 10.61

Puriblood Medical Co., Ltd. Price to Sales Ratio (P/S) is 10.61 on January 14, 2025, a -10.49% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Puriblood Medical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 11.86 on July 29, 2024, which is 11.72% above the current Price to Sales Ratio (P/S).
  • Puriblood Medical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 8.94 on November 06, 2024, which is -15.79% below the current Price to Sales Ratio (P/S).
  • Puriblood Medical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 10.16.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Taipei Exchange: 6847.TWO

Puriblood Medical Co., Ltd.

CEO Dr. Luke Chen
IPO Date Nov. 5, 2021
Location
Headquarters No.11, Gongye East 9th Road
Employees 42
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Puriblood Medical Co., Ltd. develops and sells blood cell separation products in Taiwan. The company offers leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. It also offers Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. In addition, the company develops P-Tex Technology, which is composed by bio-inspired molecular formula – zwitterionic copolymer structure. Puriblood Medical Co., Ltd. was founded in 2016 and is based in Hsinchu City, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email